Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:LNTH NASDAQ:STOK NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$39.76$35.86$10.38▼$43.73$6.79B0.342.39 million shs1.59 million shsLNTHLantheus$104.82$103.36$47.25▼$111.86$6.82B-0.06767,286 shs474,086 shsSTOKStoke Therapeutics$29.30$30.41$12.25▼$40.22$1.82B1.17766,368 shs441,833 shsXENEXenon Pharmaceuticals$65.42$58.30$30.00▼$72.66$6.32B0.611.35 million shs529,948 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences0.00%+1.74%+4.31%+8.63%+229.41%LNTHLantheus0.00%-2.57%-4.54%+24.62%+43.73%STOKStoke Therapeutics0.00%+0.86%-8.44%-13.08%+123.66%XENEXenon Pharmaceuticals0.00%-4.16%+9.51%+20.57%+115.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$39.76$35.86$10.38▼$43.73$6.79B0.342.39 million shs1.59 million shsLNTHLantheus$104.82$103.36$47.25▼$111.86$6.82B-0.06767,286 shs474,086 shsSTOKStoke Therapeutics$29.30$30.41$12.25▼$40.22$1.82B1.17766,368 shs441,833 shsXENEXenon Pharmaceuticals$65.42$58.30$30.00▼$72.66$6.32B0.611.35 million shs529,948 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences0.00%+1.74%+4.31%+8.63%+229.41%LNTHLantheus0.00%-2.57%-4.54%+24.62%+43.73%STOKStoke Therapeutics0.00%+0.86%-8.44%-13.08%+123.66%XENEXenon Pharmaceuticals0.00%-4.16%+9.51%+20.57%+115.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.85Moderate Buy$45.9015.44% UpsideLNTHLantheus 2.73Moderate Buy$110.435.35% UpsideSTOKStoke Therapeutics 2.73Moderate Buy$43.0046.76% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.2018.01% UpsideCurrent Analyst Ratings BreakdownLatest STOK, LNTH, COGT, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $125.007/15/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform ➝ Market Outperform$115.00 ➝ $120.007/13/2026STOKStoke Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.007/13/2026STOKStoke Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.007/9/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $129.007/8/2026COGTCogent Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.005/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/27/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$80.00 ➝ $82.00(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/ALNTHLantheus$1.55B4.41$6.38 per share16.42$16.43 per share6.38STOKStoke Therapeutics$184.42M9.89N/AN/A$6.17 per share4.75XENEXenon Pharmaceuticals$7.50M843.22N/AN/A$7.53 per share8.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)LNTHLantheus$233.56M$4.1525.2619.48N/A18.05%29.32%15.00%8/5/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%8/11/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%8/10/2026 (Estimated)Latest STOK, LNTH, COGT, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026STOKStoke Therapeutics-$0.82N/AN/AN/A$4.89 millionN/A8/10/2026Q2 2026XENEXenon Pharmaceuticals-$1.16N/AN/AN/A$1.67 millionN/A8/5/2026Q2 2026LNTHLantheus$1.33N/AN/AN/A$362.45 millionN/A8/4/2026Q2 2026COGTCogent Biosciences-$0.55N/AN/AN/A$0.00 millionN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent Biosciences0.4115.1415.14LNTHLantheus0.472.832.64STOKStoke TherapeuticsN/A8.998.99XENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ALNTHLantheus99.06%STOKStoke TherapeuticsN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences6.59%LNTHLantheus1.70%STOKStoke Therapeutics9.60%XENEXenon Pharmaceuticals2.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableSTOKStoke Therapeutics10062.28 million56.30 millionOptionableXENEXenon Pharmaceuticals21096.67 million93.85 millionOptionableSTOK, LNTH, COGT, and XENE HeadlinesRecent News About These CompaniesOrbimed Advisors LLC Acquires 612,771 Shares of Xenon Pharmaceuticals Inc. $XENE1 hour ago | marketbeat.comOctagon Capital Advisors LP Purchases Shares of 490,000 Xenon Pharmaceuticals Inc. $XENE1 hour ago | marketbeat.comCommodore Capital LP Trims Position in Xenon Pharmaceuticals Inc. $XENE3 hours ago | marketbeat.comAffinity Asset Advisors LLC Buys 425,000 Shares of Xenon Pharmaceuticals Inc. $XENEJuly 25 at 3:12 AM | marketbeat.comSiren L.L.C. Has $76.67 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 24 at 6:16 AM | marketbeat.comHsbc Holdings PLC Purchases New Position in Xenon Pharmaceuticals Inc. $XENEJuly 24 at 4:49 AM | marketbeat.comAtika Capital Management LLC Has $3.48 Million Stake in Xenon Pharmaceuticals Inc. $XENEJuly 24 at 3:24 AM | marketbeat.comKBC Group NV Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 23, 2026 | marketbeat.comAllspring Global Investments Holdings LLC Takes $13.96 Million Position in Xenon Pharmaceuticals Inc. $XENEJuly 22, 2026 | marketbeat.comJennison Associates LLC Has $76.69 Million Stake in Xenon Pharmaceuticals Inc. $XENEJuly 20, 2026 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by AnalystsJuly 20, 2026 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by BrokeragesJuly 20, 2026 | marketbeat.comXenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial ExecutionJuly 16, 2026 | seekingalpha.comTeachers Retirement System of The State of Kentucky Acquires New Shares in Xenon Pharmaceuticals Inc. $XENEJuly 16, 2026 | marketbeat.comCalamos Advisors LLC Makes New Investment in Xenon Pharmaceuticals Inc. $XENEJuly 16, 2026 | marketbeat.com26,200 Shares in Xenon Pharmaceuticals Inc. $XENE Bought by Swedbank ABJuly 12, 2026 | marketbeat.comCandriam S.C.A. Has $27.71 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 12, 2026 | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.com25,109 Shares in Xenon Pharmaceuticals Inc. $XENE Bought by Corient Private Wealth LLCJuly 2, 2026 | marketbeat.comPeregrine Capital Management LLC Sells 31,715 Shares of Xenon Pharmaceuticals Inc. $XENEJuly 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTOK, LNTH, COGT, and XENE Company DescriptionsCogent Biosciences NASDAQ:COGT$39.76 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$39.76 0.00 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Lantheus NASDAQ:LNTH$104.82 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$103.50 -1.32 (-1.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Stoke Therapeutics NASDAQ:STOK$29.30 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$29.82 +0.52 (+1.79%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Xenon Pharmaceuticals NASDAQ:XENE$65.42 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$63.00 -2.42 (-3.70%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
